Insider · CIK 0001342823

Glenn Gregory M

Reports to the SEC for 2 companies · ROCKVILLE, MD

sec.gov

Transactions

Companies

Filings

CIK

0001342823

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2023-03-10	NVAXNOVAVAX INCM Exercise/Conversion	President, R&D	MExercise/Conversion	+6,298 sh	$6.52	+$41.1K	20,771
2023-03-10	NVAXNOVAVAX INC · Restricted Stock UnitsM Exercise/Conversion	President, R&D	MExercise/Conversion	−6,298 sh	—	—	12,596
2023-03-10	NVAXNOVAVAX INCP Purchase	President, R&D	PPurchase	+1,000 sh	$6.50	+$6,500	14,473
2023-03-10	NVAXNOVAVAX INCF Tax Payment	President, R&D	FTax Payment	−2,432 sh	$6.52	−$15.9K	18,339
2023-03-07	NVAXNOVAVAX INCP Purchase	President, R&D	PPurchase	+2,000 sh	$7.04	+$14.1K	13,473
2023-03-06	NVAXNOVAVAX INCP Purchase	President, R&D	PPurchase	+3,000 sh	$7.48	+$22.5K	11,473
2022-12-14	NVAXNOVAVAX INCM Exercise/Conversion	President, R&D	MExercise/Conversion	+3,100 sh	—	—	9,042
2022-12-14	NVAXNOVAVAX INC · Restricted Stock UnitsM Exercise/Conversion	President, R&D	MExercise/Conversion	−3,100 sh	—	—	3,100
2022-12-14	NVAXNOVAVAX INCF Tax Payment	President, R&D	FTax Payment	−1,033 sh	$17.23	−$17.8K	8,009
2022-03-10	NVAXNOVAVAX INC · Restricted Stock UnitsA Award	President, R&D	AAward	+18.9K sh	—	—	18,894
2022-03-10	NVAXNOVAVAX INC · Stock Option (Right to Buy)A Award	President, R&D	AAward	+28.3K sh	—	—	28,341
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−91 sh	$173.29	−$15.8K	6,426
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−248 sh	$172.38	−$42.7K	6,517
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−137 sh	$174.65	−$23.9K	6,289
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−213 sh	$170.46	−$36.3K	7,019
2021-12-15	NVAXNOVAVAX INCM Exercise/Conversion	President, R&D	MExercise/Conversion	+662 sh	$46.00	+$30.5K	7,349
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−27 sh	$180.62	−$4,876.77	5,663
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−67 sh	$175.89	−$11.8K	6,222
2021-12-15	NVAXNOVAVAX INCM Exercise/Conversion	President, R&D	MExercise/Conversion	+1,024 sh	$27.60	+$28.3K	6,687
2021-12-15	NVAXNOVAVAX INC · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D	MExercise/Conversion	−662 sh	—	—	7,944
2021-12-15	NVAXNOVAVAX INC · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D	MExercise/Conversion	−1,024 sh	—	—	0
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−117 sh	$168.82	−$19.8K	7,232
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−206 sh	$179.58	−$37K	5,690
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−103 sh	$178.99	−$18.4K	5,896
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−223 sh	$176.83	−$39.4K	5,999
2021-12-15	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−254 sh	$171.47	−$43.6K	6,765
2021-12-14	NVAXNOVAVAX INCM Exercise/Conversion	President, R&D	MExercise/Conversion	+3,100 sh	—	—	7,161
2021-12-14	NVAXNOVAVAX INCF Tax Payment	President, R&D	FTax Payment	−1,498 sh	$168.43	−$252K	5,663
2021-12-14	NVAXNOVAVAX INC · Restricted Stock UnitsM Exercise/Conversion	President, R&D	MExercise/Conversion	−3,100 sh	—	—	6,200
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−500 sh	$179.36	−$89.7K	5,514
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−300 sh	$156.24	−$46.9K	11,214
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−500 sh	$180.29	−$90.1K	5,014
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−100 sh	$154.38	−$15.4K	11,514
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−100 sh	$151.85	−$15.2K	12,011
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−397 sh	$153.53	−$61K	11,614
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−200 sh	$157.02	−$31.4K	11,014
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−853 sh	$182.30	−$155K	4,161
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−300 sh	$164.77	−$49.4K	9,614
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−200 sh	$162.82	−$32.6K	9,914
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−300 sh	$165.80	−$49.7K	9,314
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−300 sh	$158.42	−$47.5K	10,714
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−300 sh	$160.52	−$48.2K	10,414
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−300 sh	$161.63	−$48.5K	10,114
2021-12-07	NVAXNOVAVAX INCM Exercise/Conversion	President, R&D	MExercise/Conversion	+8,250 sh	$19.08	+$157K	12,311
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−300 sh	$167.06	−$50.1K	9,014
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−800 sh	$176.19	−$141K	6,514
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−200 sh	$171.30	−$34.3K	8,414
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−500 sh	$178.21	−$89.1K	6,014
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−200 sh	$173.13	−$34.6K	8,214
2021-12-07	NVAXNOVAVAX INCS Sale	President, R&D	SSale	−100 sh	$182.96	−$18.3K	4,061

Recent filings

Accepted (ET)
Mar 144
Glenn Gregory M0001209191-23-018545
SEC(opens sec.gov)
Dec 164
Glenn Gregory M0001209191-22-061704
SEC(opens sec.gov)
Mar 144
Glenn Gregory M0001209191-22-018657
SEC(opens sec.gov)
Dec 164
Glenn Gregory M0001209191-21-070012
SEC(opens sec.gov)

Companies

Address

9920 BELWARD CAMPUS DRIVE

ROCKVILLE, MD, 20850